GlassScriptPhysician profile
Stacy Wilson
NPI 1194215244
$3,895.35
in general payments reported to CMS, 2019-2025
36 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $153 · 2022: $1,653 · 2023: $1,016 · 2024: $749 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,089.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $562.10 | 2022 | |
| Relievant Medsystems, INC. | $503.22 | 2021-2023 | Intracept |
| Lilly USA, LLC | $342.33 | 2022-2024 | Taltz, Mounjaro, Zepbound |
| Abbvie INC. | $297.69 | 2021-2024 | |
| Collegium Pharmaceutical, INC. | $274.82 | 2022-2025 | Xtampza, Belbuca |
| Pfizer INC. | $224.57 | 2023-2025 | |
| Vertos Medical, INC. | $209.84 | 2022-2023 | Mild Device Kit |
| Boston Scientific Corporation | $183.53 | 2024 | |
| Neurocrine Biosciences, INC. | $161.94 | 2023-2025 | Ingrezza, Ongentys |
| Biohaven Pharmaceutical Holding Company LTD. | $135.76 | 2022 | |
| Radius Health, INC. | $101.59 | 2022-2024 | Tymlos |
| Curonix LLC | $100.06 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Galt Pharmaceuticals, LLC | $98.76 | 2023 | Orphengesic Forte |
| Amgen INC. | $91.32 | 2022-2025 | Evenity, Prolia, Tavneos |
| Averitas Pharma INC. | $77.23 | 2023-2025 | Qutenza |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $67.18 | 2022-2023 | Ztlido |
| Ucb, INC. | $65.73 | 2023-2024 | Cimzia, Rystiggo |
| Indivior INC. | $64.14 | 2023-2025 | Sublocade |
| Sobi, INC | $32.72 | 2024-2025 | |
| Pacira Pharmaceuticals Incorporated | $26.39 | 2023 | Iovera, Exparel, Zilretta |
| Eisai INC. | $23.87 | 2023 | |
| Abbott Laboratories | $23.54 | 2021 | |
| Spr Therapeutics, INC | $22.23 | 2024 | Sprint Pns System |
| Globus Medical, INC. | $19.58 | 2025 | Senza |
| Medtronic, INC. | $18.28 | 2025 | Intellis Adaptivestim |
| Alvogen INC | $17.55 | 2025 | Teriparatide |
| Tg Therapeutics, INC. | $17.13 | 2021 | |
| Janssen Biotech, INC. | $16.99 | 2022 | |
| Tonix Medicines, INC. | $15.70 | 2025 | Tonmya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.68 | 2025 | Relistor |
| Btg International INC. | $15.66 | 2021 | |
| Heron Therapeutics, INC. | $14.62 | 2022 | |
| Horizon Therapeutics Plc | $14.19 | 2023 | Krystexxa |
| Csl Behring | $13.47 | 2023 | Hizentra |
| Sandoz INC. | $13.10 | 2023 | Hyrimoz |
| Stimwave Technologies Incorporated | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.